Article Text
Statistics from Altmetric.com
Description
A 82-year-old man was admitted to our institution with a 2-month history of fatigue and loss of appetite. Laboratory studies revealed anaemia, with haemoglobin level of 7.9 g/dL and a red cell count of 2.9×1012/L; the white cell count was normal. Upper endoscopy showed two discrete gastric lesions: one in the antrum, ulcerated, 5 cm in diameter; the other in the fundus, polypoid in shape, 2 cm in diameter (figure 1A,B), separated by intervening uninvolved mucosa. Biopsies demonstrated an adenocarcinoma in the antrum, and a diffuse infiltrate of large, monomorphous B-cells suspicious for lymphoma in the fundus, respectively.
Positron emission tomography/CT scan did not reveal any extragastric site of pathological 18F-fluorodeoxyglucose uptake. Therefore, a total gastrectomy with D2 lymphadenectomy was performed.
On microscopic examination (figure 1C,D), the antral lesion was a moderately differentiated, intestinal type adenocarcinoma, with regional nodal metastases. According to the American Joint Committee on Cancer Classification,1 the pathological stage was IIIA (pT4a N1).
In regards to the fundic lesion, histology showed a diffuse infiltrate of large lymphoid cells in the oxyntic mucosa, extending into the perivisceral fat and involving one perigastric lymph node. The cells were immunoreactive for CD20, CD79a, bcl-2 (>50%), IRF4/MUM1, c-myc (>40%) and negative for CD3, CD10, bcl-6 and LMP (latent membrane protein of Epstein-Barr virus (EBV)). The Ki-67 proliferation index was 90%. In situ hybridisation for EBV-encoded small RNA (EBER) was performed, and it showed a negative result in the neoplastic cells. No component of low-grade lymphoma was identified.
Rearrangements of MYC, BCL2 and BCL6 were evaluated by fluorescence in situ hybridisation (FISH), using specific probes (namely, Vysis LSI MYC Dual Color Break Apart Rearrangement Probe; Vysis LSI BCL2 Dual Color Break Apart FISH Probe; Vysis LSI BCL6 Dual Color Break Apart Rearrangement Probe; Abbott, Chicago, Illinois), with the analyses of 50 nonoverlapping nuclei. Rearrangements of MYC, BCL2 and BCL6 (figure 2) were detected in the neoplastic cells, with a percentage of rearranged nuclei of 26%, 30% and 34%, respectively.
Consequently, a diagnosis of triple-hit high-grade B-cell lymphoma was rendered, and it was confirmed to be primitive of the stomach according to Dawson’s criteria.2 3
After surgery, the patient was discharged symptom free. He received adjuvant chemotherapy with six cycles of capecitabine and rituximab and is currently in good clinical conditions, with no recurrence.
The occurrence of synchronous primary malignancies with different hystogenesis in the same organ is extremely unusual. Although adenocarcinoma and lymphoma are the two most common gastric malignancies, they rarely occur simultaneously. Moreover, the majority of these patients is diagnosed with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.4 Since the new category of double/triple-hit high-grade B-cell lymphoma was introduced in the revised edition of the WHO classification,5 this is the first case of synchronous gastric triple-hit high-grade B-cell lymphoma and gastric adenocarcinoma reported in the literature.
Given the rarity of this event, our case emphasises the importance to biopsy adequately all endoscopically visible lesions, in order to provide the best therapeutic management for this exceptional occurrence.
Learning points
The synchronous occurrence of gastric adenocarcinoma and gastric lymphoma is extremely rare, and primary gastric high-grade B-cell lymphoma with MYC, BCL2 and BCL6 rearrangements has never been described in association with gastric adenocarcinoma.
The importance of becoming proficient in the diagnosis of this exceptional association is related to the different therapeutic approaches in the treatment of lymphoma and cancer, nonsurgical for the former and surgical for the latter. Therefore, special attention should be paid to the possibility of the simultaneous occurrence of gastric adenocarcinoma and lymphoma, in order to evaluate the most effective therapy for these patients.
Ethics statements
Acknowledgments
We thank Dr Rossella Cubisino for providing endoscopic images and Dr Francesca Sanguedolce for providing EBER-ISH stain.
Footnotes
Contributors CC collected and analysed the data, drafted and revised the initial manuscript. PP and DT drafted and revised the initial manuscript. PG critically revised the manuscript for important intellectual content. All the authors read and approved the final manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.